Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry
Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.
